GLP-1 Drug Shortages Led to Worse Blood Sugar Control in Australian Diabetes Patients
When GLP-1 receptor agonist medications became scarce, patients with type 2 diabetes saw their blood sugar levels significantly worsen, with HbA1c rising by a median of 0.3%.
Quick Facts
What This Study Found
Among 811 adults with type 2 diabetes at an Australian specialist diabetes clinic, median HbA1c levels significantly increased by 0.3% during a period when GLP-1 receptor agonist medications were in short supply. The analysis covered prescriptions from January 2019 through October 2023, comparing outcomes before and during the shortage period.
A 0.3% rise in HbA1c is clinically meaningful — it reflects worsening blood sugar control that, if sustained, increases the risk of diabetes-related complications including cardiovascular disease, kidney damage, and nerve problems.
Key Numbers
How They Did This
The researchers conducted a retrospective analysis of medical records from 811 adults with type 2 diabetes attending a specialist diabetes clinic in Australia. They identified patients who had received at least two GLP-1 receptor agonist prescriptions both before and during the medication shortage period (January 2019 to October 2023) and compared their HbA1c levels across these time periods.
Why This Research Matters
GLP-1 receptor agonists have become cornerstone treatments for type 2 diabetes, but surging demand — partly driven by their use for weight loss — has created global shortages. This study provides real-world evidence that these shortages translate directly into worse health outcomes for diabetes patients who depend on these medications, highlighting the urgent need for stable drug supply chains.
The Bigger Picture
The global surge in demand for GLP-1 receptor agonists — driven by both diabetes treatment and off-label weight loss use — has created widespread supply disruptions. This study adds to growing evidence that medication shortages are not just an inconvenience but have tangible health consequences. It underscores the tension between expanding access to these popular drugs and ensuring reliable supply for patients who medically depend on them.
What This Study Doesn't Tell Us
The study was conducted at a single specialist diabetes clinic in Australia, which may not reflect outcomes at primary care settings or in other countries. The retrospective design means the researchers could not control for other factors that may have influenced blood sugar changes during the shortage period, such as patients switching to alternative medications or lifestyle changes. The abstract does not detail what patients did when they could not access their GLP-1 RA prescriptions.
Questions This Raises
- ?Did patients who switched to alternative diabetes medications during the shortage maintain better glycemic control than those who went without treatment?
- ?How long did it take for HbA1c levels to recover once GLP-1 receptor agonist supply was restored?
- ?Are certain patient subgroups — such as those on higher doses or with longer diabetes duration — more vulnerable to the effects of medication shortages?
Trust & Context
- Key Stat:
- 0.3% HbA1c increase Median rise in long-term blood sugar levels among 811 diabetes patients during GLP-1 receptor agonist shortages
- Evidence Grade:
- This is a retrospective observational study from a single specialist clinic. While it provides valuable real-world evidence with a reasonable sample size, the lack of randomization and inability to control for confounding factors limits the strength of causal conclusions.
- Study Age:
- Published in 2024, this study addresses an ongoing issue — GLP-1 receptor agonist shortages continue to affect patients worldwide, making these findings highly current and relevant.
- Original Title:
- The impact of GLP-1 receptor agonist shortages on glycaemic Control: Findings from an Australian specialist diabetes clinic.
- Published In:
- Diabetes research and clinical practice, 213, 111740 (2024)
- Database ID:
- RPEP-08933
Evidence Hierarchy
Frequently Asked Questions
What caused the GLP-1 receptor agonist shortage?
The shortage was driven by a surge in global demand for GLP-1 receptor agonists, partly due to their increasing off-label use for weight loss alongside their established role in diabetes treatment. Manufacturers struggled to scale production to meet this rapidly growing demand.
Is a 0.3% increase in HbA1c significant?
Yes, clinically a 0.3% rise in HbA1c is meaningful. Long-term studies have shown that even small sustained increases in HbA1c are associated with higher risks of diabetes complications, including heart disease, kidney damage, and nerve problems.
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-08933APA
Nanayakkara, Natalie; Lh Huang, Michael; Jenkins, Alicia J; Cohen, Neale D. (2024). The impact of GLP-1 receptor agonist shortages on glycaemic Control: Findings from an Australian specialist diabetes clinic.. Diabetes research and clinical practice, 213, 111740. https://doi.org/10.1016/j.diabres.2024.111740
MLA
Nanayakkara, Natalie, et al. "The impact of GLP-1 receptor agonist shortages on glycaemic Control: Findings from an Australian specialist diabetes clinic.." Diabetes research and clinical practice, 2024. https://doi.org/10.1016/j.diabres.2024.111740
RethinkPeptides
RethinkPeptides Research Database. "The impact of GLP-1 receptor agonist shortages on glycaemic ..." RPEP-08933. Retrieved from https://rethinkpeptides.com/research/nanayakkara-2024-the-impact-of-glp1
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.